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AbsTrACT
Objective Myelin oligodendrocyte glycoprotein- 
associated disorders (MOgaDs) are a rare new 
neurological autoimmune disease with unclear 
pathogenesis. since a linkage of the disease to the 
human leucocyte antigen (hla) has not been shown, we 
here investigated whether MOgaD is associated with the 
hla locus.
Methods hla genotypes of 95 patients with MOgaDs, 
assessed between 2016 and 2018 from three academic 
centres, were compared with 481 healthy chinese 
han individuals. Patients with MOgaDs included 
51 paediatric- onset and 44 adult- onset cases. all 
patients were seropositive for igg targeting the myelin 
oligodendrocyte glycoprotein (MOg).
results Paediatric- onset MOgaD was associated 
with the DQB1*05:02–DRB1*16:02 alleles (Or=2.43; 
Or=3.28) or haplotype (Or=2.84) of HLA class ii 
genes. The prevalence of these genotypes in patients 
with paediatric- onset MOgaD was significantly higher 
than healthy controls (padj=0.0154; padj=0.0221; 
padj=0.0331). By contrast, adult- onset MOgaD was 
not associated with any hla genotype. clinically, 
patients with the DQB1*05:02–DRB1*16:02 haplotype 
exhibited significantly higher expanded disability status 
scale scores at onset (p=0.004) and were more likely 
to undergo a disease relapse (p=0.030). hla–peptide 
binding prediction algorithms and computational 
docking analysis provided supporting evidence for the 
close relationship between the MOg peptide subunit 
and DQB1*05:02 allele. in vitro results indicated that 
site- specific mutations of the predicted target sequence 
reduced the antigen–antibody binding, especially in the 
paediatric- onset group with DQB1*05:02 allele.
Conclusions This study demonstrates a possible 
association between specific HLA class ii alleles and 
paediatric- onset MOgaD, providing evidence for the 
conjecture that different aetiology and pathogenesis 
likely underlie paediatric- onset and adult- onset cases of 
MOgaD.
INTrOduCTION
Myelin oligodendrocyte glycoprotein- associated 
disorders (MOGADs) refer to a newly described 
group of neurological autoimmune diseases, char-
acterised by seropositivity for IgG targeting the 
MOG (MOG- IgG).1 2 Some researchers consider 
that MOGAD is a distinct disease entity, immu-
nopathologically different from the conventional 
multiple sclerosis and aquaporin-4 (AQP4)- IgG- 
positive neuromyelitis optica spectrum disorders 
(NMOSDs), and has distinct clinical manifestations, 
treatment response and prognosis.2–4 The patho-
genesis of MOGAD is not fully understood, and the 
potential genetic risk factors have not been studied 
previously.
Compared with other idiopathic inflammatory 
demyelination diseases, MOGAD more commonly 
occurs in children, and exhibits a relapsing course 
in some patients. Although glucocorticoid therapy 
is effective for the treatment of MOGADs, some 
patients showed steroid sensitive and reduction can 
lead to relapse. Multiple studies have reported age- 
dependent autoimmunity related to the frequency 
and titres of MOG- IgG.5 6 Young children with 
MOGADs often present with acute disseminated 
encephalomyelitis (ADEM), whereas older children 
and adults often exhibit recurrent optic neuritis, 
myelitis and brainstem encephalitis.7 Clinical 
phenotypes at onset are more frequently charac-
terised by encephalopathy in paediatric patients 
with MOGADs, while older patients often exhibit 
ON.8 9 MOG- IgG titres are also significantly higher 
in paediatric patients than in adults.10 11 The differ-
ences in multiple features among patients with 
paediatric- onset and adult- onset MOGADs suggest 
different underlying pathogenetic mechanisms, 
which are still unclear.
Among genes that predispose individuals to 
systemic or neurological autoimmune diseases, 
the human leucocyte antigen (HLA) gene is poten-
tially the most relevant and crucial candidate.12 13 
Most autoimmune neurological disorders, such as 
multiple sclerosis, NMOSDs and anti- N- methyl- D- 
aspartate receptor encephalitis, are associated with 
specific HLA loci, especially the class II loci,14–16 
suggesting an important role of antigen presentation 
in the pathogenesis of these diseases. In this study, 
we aimed to investigate the potential association 
between HLA locus and MOGADs, and explore 
the implications of these unique HLA subtypes in 
the immunopathogenesis of MOGADs. We hypoth-
esised that HLA might be involved in the patho-
genesis of MOGADs, and due to the differences in 
disease characteristics, there may be different asso-
ciations of HLA between children and adults.
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Figure 1 Flowchart of patient cohort enrolment and exclusion. Overall, 3108 patients with iiDDs were screened for MOg- igg, and only 186 positive 
cases were identified. Of these, 71 patients did not have enough samples for Dna extraction and 12 patients were lost to follow- up. in several patients, 
diseases other than iiDDs were identified, and several patients were anti- nMDar antibody positive. eventually, 44 patients comprised the adult- onset MOg- 
encephalomyelitis cohort and 51 patients comprised the paediatric- onset cohort. cns, central nervous system; iiDDs, idiopathic inflammatory demyelination 
diseases; MOg- igg, myelin oligodendrocyte glycoprotein- immunoglobulin g; nMDar, N- methyl- D- aspartate receptor.
subjeCTs ANd MeThOds
subjects
From March 2016 to December 2018, 3108 patients from 
three academic centres (the Third Affiliated Hospital of Sun 
Yat- sen University, Zhongshan Ophthalmic Center of Sun Yat- 
sen University and Guangzhou Women and Children Medical 
Centre) in Guangzhou were referred to our laboratory for 
serum MOG- IgG testing. All patients had clinical manifesta-
tions related to central nervous system (CNS) demyelinating 
diseases and were tested for serum MOG- IgG and AQP4- IgG 
by a cell- based assay (CBA), as described previously.8 In total, 
186 patients were seropositive for MOG- IgG, and 71 of them 
had no peripheral blood specimens stored after the test. A total 
of 115 MOG- IgG- positive patients were collected and followed 
up every 2 months in this study. The end time of follow- up was 
April 2019 and no other follow- up end point was set artificially. 
Twelve patients were lost to follow- up or the follow- up time 
was less than 4 months. After follow- up, 8 patients were finally 
diagnosed with non- CNS inflammatory demyelinating disease. 
Therefore, 95 patients were finally included in this study as the 
overall cohort, and they were all Han Chinese (figure 1). Final 
diagnoses were reported by the referring centres during the last 
follow- up and were based on the 2015 Wingerchuk criteria for 
NMOSDs,17 the 2017 McDonald criteria for multiple sclerosis18 
and the 2012 criteria for ADEM.19 Relapse was defined as the 
sudden emergence of new symptoms lasting over 24 hours and 
separated by at least 1 month since the last episode. Expanded 
Disability Status Scale (EDSS) scores were evaluated at the peak 
of recurrence. Written informed consent was obtained from all 
patients or their representatives, and in the case of paediatric 
patients, consent was signed by the legal guardian.
Molecular cloning and CbA
Full- length human MOG (Hu- MOG) was subcloned into the 
internal ribosome entry site 2- enhanced green fluorescent 
protein (pIRES2- EGFP) plasmid. We mutated the 42nd amino 
acid of the Hu- MOG protein from proline (P) to serine (S) 
(Hu- P42S) and subcloned it into the same expression vector. 
These constructs comprised a C- terminal EGFP- tag. Using the 
QuikChange Site- Directed Mutagenesis Kit (Stratagene, Santa 
Clara, California, USA), point mutations were introduced into 
Hu- MOG gene. The oligonucleotides used were 5′– GTGG 
GGTG GTAC CGCT CCCC CTTC TCTA GGGTG–3′ (P42S) and 
the corresponding reverse complementary oligonucleotides.
Hu- MOG and Hu- P42S plasmids were transiently transfected 
into HEK293T cells using Lipofectamine2000 (Thermo Scien-
tific, Carisbad, CA, USA). HEK293T cells were blocked with 
goat serum and immunolabelled with AlexaFluor 546- tagged 
secondary antibody against human IgG (1:1000; Thermo Scien-
tific). Immunofluorescent images were acquired using a Zeiss 
Axiovert A1 fluorescence microscope (online supplementary 
figure 1). Each positive sample was independently tested at least 
twice.
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Current age, years, median 
(range)
16 (3–68) 10 (3–18) 32 (17–68) –
Age of onset, years, median 
(range)
13 (2–67) 8 (2–14) 30 (15–67) –
Follow- up time, months, 
median (range)
12(4–36) 12(4–36) 12(4–30) –
Inducement, n (%)   
  Previous infection 22 (23) 18 (35) 4 (9) 0.031
  Vaccine 3 (3) 2 (4) 1 (2) >0.999
  Others 3 (3) 1 (2) 2 (5) 0.595
Phenotype at onset, n (%)*   
  ON 58 (61) 25 (49) 33 (75) 0.012
  Myelitis 11 (12) 4 (8) 7 (16) 0.336
  Encephalopathy 30 (32) 26 (51) 4 (9) <0.0001
  Brainstem syndrome 6 (6) 4 (8) 2 (5) 0.683
  Others 4 (4) 3 (6) 1 (2) 0.621
Initial EDSS, median (range) 3 (1–8) 3 (1–8) 2 (1–5) 0.024
Time to relapse, m median 
(range)†
8 (1–81) 10 (1–51) 8 (1–81) 0.480
Relapse type, n (%)*†   
  ON 56 (54) 19 (40) 37 (66) 0.011
  Myelitis 17 (17) 4 (9) 13 (23) 0.062
  Encephalopathy 31 (30) 23 (49) 8 (14) <0.001
  Brainstem syndrome 9 (9) 4 (9) 5 (9) >0.999
  Others 1 (1) 0 1 (2) >0.999
Acute phase treatment, n (%)   
  Intravenous MTP 85/95 (90) 47/51 (92) 38/44 (86) 0.506
  intravenous IG 13/95 (14) 12/51 (24) 1/44 (2) 0.025
  PLEX or IAD 2/95 (2) 1/51 (2) 1/44 (2) >0.999
  None or others 7/95 (7) 3/51 (6) 4/44 (9) 0.701
Chronic therapies, n (%)   
  Steroids 67/95 (71) 34/51 (67) 33/44 (75) 0.499
Immunosuppressive 
therapies
18/95 (19) 7/51 (14) 11/44 (25) 0.195
Immunomodulatory 
therapies
7/95 (7) 5/51 (10) 2/44 (5) 0.448
Values in bold indicate that there are differences between adults and paediatric 
individuals (p<0.05).
*Patients may exhibit multiple phenotypes simultaneously.
†Forty- six patients relapsed for a total of 103 relapses; 23 paediatric- onset patients 
with 47 relapses and 23 adult- onset patients with 56 relapses.
EDSS, Expanded Disability Status Scale; IAD, immunoadsorption; MOGADs, myelin 
oligodendrocyte glycoprotein- associated disorders; MTP, methylprednisolone; ON, 
optic neuritis; PLEX, plasma exchange.
hLA genotyping
Blood samples from all patients were collected and stored at 
−80°C. Genomic DNA was extracted from the peripheral 
blood of each patient with MOGADs and HLA genotyping 
was performed as described previously.20 Briefly, the HLA class 
I (HLA- A, B and C) and class II (DRB1, DOA1, DQB1, DPA1, 
DPB1) genotypes for each patient were determined at the four- 
digit allele level using a PCR sequence- based typing method. The 
HLA frequencies of 481 geographically and ethnically matched 
healthy controls were derived from previous reports, in which 
all samples were from the Southern Han voluntary donors of 
haematopoietic stem cells from the Shenzhen Branch of China 
bone marrow bank. The exact beforementioned HLA geno-
typing method was used for genotyping the control group.20
hLA–peptide binding prediction
The NetMHCIIpan V.3.2 server was utilised for HLA class II 
peptide- binding prediction.21 The MOG protein sequence 
obtained from the National Centre for Biotechnology Informa-
tion (NCBI accession number: NP_996532.2) was submitted to 
the server. Finally, DQB1*05:02 and DRB1*16:02 were selected 
and compared in order to predict the binding epitopes within 
the protein.
In silico docking
We performed computational docking to describe the binding of 
the DQB1*05:02 and the MOG segment (predicted by the above 
method). Since the crystallographic structure of DQB1*05:02 
has not been experimentally determined, a heterodimer struc-
ture including DQB1*05:02 was created by homology model-
ling using a Swiss- Model from the HLA- DQB1*02:01 template 
structure (Protein Data Bank code 4d8p). Tertiary structure 
modelling and peptide docking were performed as described 
previously.16 AutoDockTools was used to add hydrogens, assign 
charges and specify rotatable bonds to the proteins.22 MOG 
segment docking to DQB1*05:02 was performed using the 
AutoDockVina software with the docking grid encompassing the 
entire peptide- binding cleft and the option ‘number of torsions’ 
being set to 0.23
statistical analyses
Fisher’s exact test was used to compare the frequencies of the 
various HLA alleles or haplotypes between the MOGADs and 
control groups. The degree of association between the HLA 
data and MOGADs was expressed as the OR and 95% CIs. The 
p values determined by Fisher’s exact test were adjusted for 
multiple testing with the false discovery rate criterion proposed by 
Benjamini and Hochberg. Only the adjusted p (padj) values under 
0.05 (two- tailed) were considered to be statistically significant. 
To assess the significance of clinical variables between groups, 
Mann- Whitney tests and Fisher’s exact test were performed for 
data lacking a normal distribution. All statistical analyses were 
conducted using GraphPad Prism V.7.0 and R- studio.
resuLTs
demographic and clinical status of patients with MOGAds
As described in the Subjects and methods section, all the 
serum tests were conducted by experienced testing personnel 
through CBA method and all the MOGADs were diagnosed by 
two neurologists separately, according to the 2018 MOGADs 
consensus.24 25 A total of 95 patients with MOGADs were 
enrolled, including 51 cases of paediatric- onset MOGADs (≤14 
years old) and 44 cases of adult- onset (>14 years old, figure 1). 
The clinical data for all patients are listed in table 1. Eighteen 
(35%) paediatric patients had a previous infection before onset, 
whereas only four adults had a previous infection (p=0.031). 
Adult- onset patients were more likely to have an initial ON- like 
phenotype than paediatric- onset patients (25 vs 33, p=0.012), 
while the paediatric patients more often had an initial enceph-
alopathy phenotype (26 vs 4, p<0.0001). Initial EDSS scores 
were higher among paediatric- onset patients, implying a more 
severe clinical attack (3 vs 2, p=0.024).
hLA genotypes in patients with MOGAds and healthy controls
First, the frequencies of HLA class I and II alleles were compared 
between the 95 patients and 481 healthy controls. Among patients, 
the frequency of the DQB1*05:02 allele was 18.95%, whereas 
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Table 2 HLA alleles in patients with MOGADs and in healthy controls
HLA allele
Patients (n=95 × 2) Controls (n=481 × 2)
P value Padj value Or (95% CI)Positive Negative Freq Positive Negative Freq
DQB1*05:02 36 154 0.1895 103 859 0.1071 0.0023 0.0316 1.95 (1.25 to 3.00)
DPB1*13:01 7 183 0.0368 82 880 0.0852 0.0246 0.1105 0.41 (0.16 to 0.91)
DRB1*08:03 4 186 0.0211 69 893 0.0717 0.0055 0.1278 0.28 (0.07 to 0.76)
DRB1*16:02 17 173 0.0895 41 921 0.0426 0.0106 0.1278 2.21 (1.15 to 4.08)
DPA1*02:02 124 66 0.6526 550 412 0.5717 0.0438 0.1754 1.41 (1.01 to 1.98)
DQA1*01:02 51 139 0.2684 192 770 0.1996 0.0407 0.2215 1.47 (1.01 to 2.13)
DQA1*01:03 7 183 0.0368 79 883 0.0821 0.0332 0.2215 0.43 (0.16 to 0.94)
DRB1*14:05 8 182 0.0421 16 946 0.0166 0.0446 0.2675 2.60 (0.95 to 6.54)
DRB1*15:02 11 179 0.0579 26 936 0.0270 0.0397 0.2675 2.21 (0.97 to 4.73)
DQB1*05:03 15 175 0.0789 40 922 0.0416 0.0385 0.2697 1.97 (0.99 to 3.75)
C*07:02 22 168 0.1158 171 791 0.1778 0.0429 0.3144 0.61 (0.36 to 0.98)
C*06:02 2 188 0.0105 38 924 0.0395 0.0493 0.3144 0.26 (0.03 to 1.02)
A*02:07 34 156 0.1789 119 843 0.1237 0.0465 0.4683 1.54 (0.98 to 2.37)
Table shows only HLA alleles with an unadjusted p value of <0.05. P values are adjusted for multiple testing via the FDR step- up method.
FDR, false discovery rate; freq, frequency; HLA, human leucocyte antigen; MOGADs, myelin oligodendrocyte glycoprotein- associated disorders.
Figure 2 Frequencies of significant alleles and haplotypes in patients 
with MOgaDs and controls. comparison of the allele frequencies of 
(a) DQB1*05:02, (B) DRB1*16:02 and (c) DRB1*16:02–DQB1*05:02 
haplotypes among controls, all patients and patients with paediatric- onset 
and adult- onset MOgaDs. *P<0.05. MOgaDs, myelin oligodendrocyte 
glycoprotein- associated disorders.
Table 3 Association between DQB1*05:02–DRB1*16:02 haplotype 
and clinical features in paediatric- onset patients with MOGADs
Patients with 
haplotype n=10 Controls n=41 P value
Age, years, median (range) 11 (3–16) 10 (3–18) –
Age of onset, years, median (range) 4 (2–14) 8 (2–13) –
Inducement, n (%)   
  Previous infection 3 (30) 15 (38) 0.730
Phenotype at onset, n (%)*   
  ON 5 (50) 20 (49) >0.999
  Myelitis 2 (20) 2 (5) 0.168
  Encephalopathy 5 (50) 21 (51) >0.999
  Brainstem syndrome 0 4 (10) 0.573
  Others 0 3 (7) >0.999
Initial EDSS, median (range) 4.25 (2–8) 3 (1–6.5) 0.004
Baseline titre, median (range) 320 (100–640) 100 (100–1280) 0.387
Patients with relapse, n (%) 8 (80) 15 (37) 0.030
Relapse type, n (%)*   
  ON 9/16 (56) 10/31 (32) 0.131
  Myelitis 2/16 (13) 2/31 (7) 0.597
  Encephalopathy 6/16 (38) 18/31 (58) 0.227
  Brainstem syndrome 0 4/31 (13) 0.284
*Patients may exhibit multiple phenotypes simultaneously.
EDSS, Expanded Disability Status Scale; MOGADs, myelin oligodendrocyte glycoprotein- associated 
disorders; ON, optic neuritis.
for controls it was only 10.71% (OR=1.95, 95% CI=1.25–3.0, 
p=0.002, padj=0.031 table 2, online supplementary table 1). 
Notably, when a comparison was conducted between the 51 
paediatric- onset patients and 481 healthy controls, a more signifi-
cant association was identified between DQB1*05:02 (OR=2.43, 
95% CI=1.39–4.11, p=0.001, padj=0.015) and DRB1*16:02 
(OR=3.28, 95% CI=1.55–6.25, p=0.001, padj=0.022, online 
supplementary table 2, figure 2) and disease. Furthermore, we 
found that the frequency of the DQB1*05:02–DRB1*16:02 haplo-
type was higher in paediatric- onset patients than in healthy controls 
(OR=2.84, 95% CI=1.17–6.36, p=0.0165, padj=0.0331), though 
this difference was not statistically significant for all patients after 
correction (p=0.0478, padj=0.0956). Interestingly, adult- onset 
patients yielded no specific association with any HLA alleles 
(online supplementary table 3, figure 2).
Association between DQB1*05:02–DRB1*16:02 haplotype 
and clinical data of patients with MOGAds
We next investigated DQB1*05:02–DRB1*16:02 haplotype’s 
association with the clinical features of the paediatric- onset 
patients with MOGADs by comparing the DQB1*05:02–
DRB1*16:02 carriers with the DQB1*05:02–DRB1*16:02 
non- carriers. As shown in table 3, the two patient subgroups 
were comparable in age, initial EDSS and relapse frequency. 
However, patients carrying the DQB1*05:02–DRB1*16:02 
haplotype exhibited more severe clinical symptoms, signifi-
cantly higher initial EDSS scores (4.25 vs 3, p=0.004) and more 
frequent relapses (8/10 vs 15/41, p=0.030, table 3). The number 
of DQB1*05:02–DRB1*16:02 carriers in adult group was too 
small to determine any statistical significance.
hLA–MOG binding prediction and computational docking
The potential association between the various HLA subtypes and 
MOGADs led us to produce the HLA peptide- binding predic-
tion algorithms. Using the NetMHCIIpan V.3.2 server as a tool 
for analysis, we identified an epitope within the MOG that was 
predicted to be recognised by DQB1*05:02. This epitope with 
the target sequence ‘VGWYRPPFS’, is located at the 37th amino 
acid position in the MOG protein’s N- terminus. Therefore, the 
sequence ‘VGWYRPPFS’, which is part of the MOG protein’s 
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Figure 4 Mutation of the specific site of the target sequence 
(VgWYrPPFs) reduces the ability of antigen–antibody binding especially 
in paediatric- onset group with DQB1*05:02. (a) heK293T cells were 
transiently transfected with full- length human MOg (hu- MOg) or an 
MOg mutation plasmid (hu- P42s) and patient serum tested by an in- 
house cBa. Binding of igg from patient serum using an anti- human igg 
antibody (red) to cells transfected with MOg (green), merged images 
(yellow). some patients’ serum could only be bound to hu- MOg but not 
to hu- P42s. scale bar=20 µm. (B) Overall, 95 seropositive samples for 
MOg- igg were detected with hu- P42s, and the percentage of patients 
with positive or negative signals were compared in four groups, including 
paediatric- onset patients with a DQB1*05:02 allele, adult- onset patients 
with a DQB1*05:02 allele, paediatric- onset patients with other HLA alleles 
and adult- onset patients with other HLA alleles. * P<0.05. cBa, cell- 
based assay; hla, human leucocyte antigen; MOg, myelin oligodendrocyte 
glycoprotein; MOg- igg, myelin oligodendrocyte glycoprotein- 
immunoglobulin g.
Figure 3 computational docking of the MOg segment VgWYrPPFs to 
the hla- DQB1*05:02 heterodimer and structure of the MOg protein. (a) 
in silico docking simulation resulted in the placement of the MOg segment 
within the peptide- binding groove between hla- DQB1*05:02 and hla- 
DQa1 with docking scores (∆g) of −10.4 kcal/mol. Mesh on the surface of 
hla indicates close contact between the atoms and MOg protein segment. 
The ribbon structure shows the ligand- binding domains. (B) The structure of 
the MOg protein and the blue sections indicate the location of the peptide 
segment. hla, human leucocyte antigen; MOg, myelin oligodendrocyte 
glycoprotein.
extracellular domain, has a high probability of binding to the 
DQB1*05:02 protein.
To further evaluate the relationship between the predicted 
epitope and major histocompatibility complex (MHC) II mole-
cules, we performed an in silico docking of the ligand to the 
DQB1*05:02 protein. Computational docking determined 
that the target sequence ‘VGWYRPPFS’ fit precisely into the 
peptide- binding groove between DQB1*05:02 and HLA- DQA1, 
with a docking score (∆G) of −10.4 kcal/mol (figure 3). This in 
silico docking result suggests a positive interaction between the 
predicted epitope and DQB1*05:02.
Mutation of a VGWYrPPFs-specific site reduces the ability of 
antigen–antibody binding
A homology comparison between the humans, rats and mice 
protein sequences shows that the target sequence is conserved 
except for the P locus, which is a S locus in rats and mice. Since 
it has been reported that this site affects the binding of the MOG 
antigen and antibodies,26 we chose this site for the mutation. The 
mutant plasmid Hu- P42S was constructed as described in the 
Subjects and methods section. The Hu- P42S plasmid was tran-
siently transfected into HEK293T cells and 95 samples, that sero-
positive for MOG- IgG, were detected. The results showed that 
mutations of the predicted target sequence reduced the ability of 
antigen–antibody binding, especially in the paediatric- onset group 
with the DQB1*05:02 allele. Overall, in 74% of the 19 paediatric- 
onset patients with the DQB1*05:02 allele, no positive signals 
were observed, which was statistically significant compared with 
the adult group (p=0.016) and the paediatric- onset group with 
the other HLA allele (p=0.047) (figure 4). The 42nd amino acid 
of the Hu- MOG was included in the predicted target peptide 
VGWYRPPFS, suggesting that this peptide contained important 
antigen–antibody binding sites, and that the DQB1*05:02 allele 
was involved only in paediatric- onset MOGADs.
dIsCussION
As a new disease entity, the pathogenesis of MOGADs is still 
unclear, and there are currently no reports of its potential associ-
ation with the HLA loci. MOG- IgG, the biomarker of MOGADs, 
was first identified in patients with CNS demyelinating diseases.27 
While the presence of the DPB1*05:01 allele is a known risk 
factor for NMOSDs in Japanese and Southern Han Chinese popu-
lations,28 29 it also leads to an increased incidence of AQP4- IgG 
positivity in patients with NMOSDs. The DRB1*09:01 allele has 
also been reported to be a protective factor in both multiple scle-
rosis and NMOSDs in the Japanese and Chinese patients.15 28 30 
DRB1*15:01–DQB1*06:02 alleles are the major susceptible HLA 
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subtypes in multiple sclerosis and are usually inherited as haplo-
types due to linkage disequilibrium.14 30 In this study, MOGAD was 
found, for the first time, to be associated with the DQB1*05:02–
DRB1*16:02 alleles or haplotype of HLA class II genes in Chinese 
paediatric- onset patients. These susceptible loci differed from 
those associated with NMOSDs and multiple sclerosis, indicating a 
distinct pathogenesis for MOGADs.
The DQB1*05:02 and DRB1*16:02 alleles have also been asso-
ciated with an increased risk for several autoimmune diseases. The 
DQB1*05:02 allele is associated with relapsing polychondritis,31 
the muscle- specific kinase antibody positive in patients with myas-
thenia gravis (MG, MuSK- MG),32 33 and anti- acetylcholine receptor 
MG.31 The DRB1*16:02 allele is positively correlated with Graves' 
disease,34 anti- topoisomerase I autoantibody- positive systemic 
sclerosis35 and AQP4- IgG- positive NMOSDs.15 In relapsing poly-
chondritis and MG, both DQB1*05:02–DRB1*16 alleles and 
haplotypes are involved. Interestingly, these autoimmune diseases 
are predominantly mediated by autoantibodies, suggesting that 
DQB1*05:02 and DRB1*16:02 may play an important role in 
autoantibody production.
MOG- IgG can be detected in both paediatric and adult 
patients and recent studies have focused on the clinical differ-
ences between these two groups. MOG- IgG is found more often 
in children than in adults and the associated disease classification 
is often associated with a monophasic course.10 36 The results 
of this study demonstrate that only paediatric- onset MOGAD 
is associated with unique HLA subtypes, as adult- onset patients 
with MOGADs do not exhibit any specific association with 
HLA alleles or haplotypes. The inability to reach a statistical 
significance may be due to the small adult group size. Besides 
susceptibility, our study also showed a relationship between the 
presence of the DQB1*05:02–DRB1*16:02 haplotype and clin-
ical features. Patients carrying the haplotype had a significantly 
worse level of disability and disease relapse. These findings 
provide genetic evidence for multiple pathogenic mechanisms 
that differ between paediatric- onset and adult- onset MOGADs 
and suggest that different clinical therapies may be required. 
The pathogenesis of MOGADs is still unclear, and as an auto-
immune disease, multiple contributing genetic and environ-
mental factors may be involved. While HLA subtypes could 
be potential genetic risk factors, it cannot explain all aspects 
of the MOGADs. As there are many differences between chil-
dren and adults regarding diet, living habits and vaccination and 
so on, it may lead to differences in disease susceptibility. The 
differences in the development of the blood–brain barrier and 
maturation of the immune system among children and adults 
may also result in the differential disease phenotype and clinical 
characteristics of patients with MOG- IgG with different ages at 
onset. We hypothesise that some characteristics of children make 
them more susceptible and thereby highlight the variable impact 
of HLA. This, however, requires further research for definite 
confirmation.
The HLA system is known to be high polymorphic, and the 
distribution and frequencies of HLA alleles are highly variable 
among the different ethnic groups. Due to the different frequen-
cies of the alleles among populations, the association between 
specific diseases and HLA loci tends to be population-specific. As 
far as we know, similar results may be obtained for ethnic groups 
with a similar genetic background. For example, in Cauca-
sians, DRB1*15:01–DQB1*06:02 alleles have been consistently 
associated with susceptibility to multiple sclerosis,14 whereas 
the DPB1*05:01 allele confers susceptibility to anti- AQP4 
antibody- positive NMOSDs in the Japanese and Southern Han 
Chinese populations.28 29 In this study, MOGAD was found to be 
associated with the DQB1*05:02–DRB1*16:02 alleles or haplo-
type in the Chinese paediatric- onset patients. Although no other 
report exists on the potential association between HLA loci and 
MOGADs, we believe that this result may be applicable to other 
cohorts, at least in Asian populations with a similar HLA genetic 
background. It is worth mentioning that the difference in HLA 
association between the paediatric- onset and adult- onset patients 
with MOGADs in this study may also be applicable to non- Asian 
populations. While, further studies that include a larger number 
of patients and various populations are required to confirm these 
results.
Interestingly, bioinformatic analyses also predicted a strong 
epitope (target sequence: VGWYRPPFS) for the DQB1*05:02 
protein. This target sequence is located between aa37 and aa45 
relative to the N- terminus of the MOG protein, which is part 
of the N- terminal extracellular domain (aa1–121). The extracel-
lular region of the MOG protein also contains major T cell and B 
cell epitopes,37 38 as well as the epitope for the antibody–antigen 
interactions responsible for the formation of pathogenic anti-
bodies.37 39 Furthermore, MOG peptides (aa35–55) are highly 
encephalitogenic and can induce experimental autoimmune 
encephalomyelitis in animals.40 In animal models, the anti- MOG 
immune response can be modified by MHC haplotypes,40 but in 
humans, the mechanisms by which they act are still undefined. 
Our study shows that mutation of the 42nd amino acid of MOG 
reduces the ability of antigen–antibody binding, especially in the 
paediatric- onset group with DQB1*05:02. Collectively, these 
results suggest that HLA- DQB1*05:02 plays a role in the patho-
genesis of MOGADs and may be a possible reason that some 
carriers differed from others in their responses to the treatment.
This study had several limitations. First, the size of patient 
samples in this study was relatively small and the delineation 
of different ages cut- off for paediatric/adult onset of the cohort 
may affect the results; therefore, further studies with a larger 
number of patients are required to confirm these results. Second, 
since the HLA gene has a high degree of polymorphism as well 
as regional and ethnic distribution differences, the association 
between HLA subtypes and MOGADs seems to be popula-
tion specific. Finally, the carrier frequencies of DQB1*05:02–
DRB1*16:02 alleles or haplotype were rather low (≤30%) in 
patients with MOGADs, suggesting the existence of other poten-
tial features in the disease course that may have contributed to 
the different presentations between paediatric- onset and adults- 
onset patients with MOGADs.
In summary, to the best of our knowledge, the present study 
is the first to demonstrate that the DQB1*05:02–DRB1*16:02 
alleles or haplotype are associated with paediatric- onset 
MOGADs, in terms of both disease susceptibility and clinical 
severity. Our findings suggest that these HLA genotypes are 
risk factors for paediatric- onset MOGADs and represent a 
predictive factor for more severe clinical symptoms. This study 
also provides valuable insight into a novel disease mechanism, 
although further studies are needed to validate this association 
and explore the underlying mechanism.
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